RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

Shares of Rallybio Corporation (RLYB) tanked 41.2% on April 8 after the company announced its decision to stop the development of RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).The company decided to stop the development of RLYB212 after pharmacokinetic (PK) data from a phase II study showed that treatment with the candidate failed to achieve predicted target concentrations of 6 ng/mL to 10, as well as the minimum target concentration required for efficacy of 3 ng/mL.Th ...